A part of Watch Media

Thursday8 June 2023

Thursday8 June 2023

Photo: Anna Gordon/Reuters/Ritzau Scanpix

EU Commission approves first RSV vaccine for people over 60

A recommendation from the EMA’s expert panel from earlier this year has now been cemented.

For subscribers

Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: Snipr Biome/pr

Snipr Biome shelves lead candidate: "It’s hard to make money within AMR"

For subscribers

Photo: George Frey/Reuters/Ritzau Scanpix

UK looks to expand obesity-drug access with pilot program

For subscribers

Photo: George Frey/Reuters/Ritzau Scanpix

Denmark warns against overtreatment with Ozempic

For subscribers

Photo: Darron Cummings/AP/Ritzau Scanpix

Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rules

For subscribers

Photo: Brendan Mcdermid/Reuters/Ritzau Scanpix

Merck sues US, calling move to cut drug prices "extortion"

For subscribers

Analyst predicts golden future for GLP-1 as drugmakers rush to join in
Novo Nordisk’s launch of weight-loss drug Wegovy has pushed the market for the medical treatment of chronic diseases like diabetes and obesity.
For subscribers
Zealand Pharma reprimanded by Danish watchdog following sale of rescue pen to Novo Nordisk
The biotech company classified information as internal knowledge too late when negotiating a deal with Novo Nordisk, says the Danish Financial Supervisory Authority.
For subscribers
US contract manufacturer acquires Danish consultancy firm
Medical device maker MGS is taking over another company in Denmark.
For subscribers
Genmab approval marks the era of bispecific antibodies in blood cancer treatment, says expert
In coming years, doctors will receive more ways to treat patients with hematologic cancers.
For subscribers
Eisai hit by ransomware attack
Pharmaceutical firm Eisai informs that it will take some time to understand the full scope of the incident and that recovery efforts have been initiated.
For subscribers
GPT AI has arrived in the doctor's office
Artificial is now taking notes for doctors, allowing them to focus on patients. ”This type of technology will make doctors more likely to stay in their jobs,” says Carbon Health’s innovation officer.
For subscribers
Denmark warns of Novo Nordisk diabetes drug shortage
As soon as mid-July, the Danish Medicines Agency expects supply improvements from the drugmaker.
For subscribers
Sobi partners with ViroGates on Covid-19 combination treatment for US market
Danish diagnostics firm ViroGates and Swedish Sobi look forward to commencing dialogs with the US drug authority.
For subscribers
Nanexa preparing for phase I trial of Novo Nordisk drug in slow-release injection
A depot injection of liraglutide would simplify treatment for patients with obesity and diabetes, says Nanexa, which is gearing up to start testing later this year.
For subscribers
Pfizer presents promising phase III data for new antibiotic treatment
A new combination treatment from Pfizer shows strong effects in a late-stage trial treating serious infections caused by drug-resistant bacteria.
For subscribers
Novo Nordisk to buy French developer of digital injection pen add-on
After around two years of being partnered, the Danish drugmaker wants to take over Biocorp.
For subscribers
Novo Nordisk maintains its defense in case of high-priced insulin – competitor enters settlement
Novo Nordisk rejects the US charges of price fixing for insulin while competitor Eli Lilly settles in the case.
Multi-cancer blood test spots two in three cases in UK study
A blood test for over 50 types of cancer correctly identified the disease in two-thirds of cases in a major trial in England and Wales.
For subscribers
NICE approves migraine wafer from Pfizer
The British regulatory body, NICE, has approved the wafer Vydura from Biohaven/Pfizer as a preventive measure against migraines but not as acute treatment.
For subscribers
ALK pushed out of leading European index
The allergy company will be replaced by a Danish cable manufacturer.
Eli Lilly enters multimillion-dollar settlement on US insulin prices
Novo Nordisk and Sanofi aren’t entailed by the settlement in the class-action lawsuit that claims the three companies simultaneously overpriced their insulin products.
For subscribers
Novo Nordisk launches another phase III study of Genmab-developed hemophilia drug
A new phase III study will test the safety of switching from Roche’s blockbuster medicine to Novo Nordisk’s similar solution for people with a bleeding disorder.
For subscribers
Nykode expands collaboration with Roche on cervical cancer vaccine
A new study of Nykode’s vaccine candidate in combination with Roche’s Tecentriq will hopefully give patients access to new treatment.
For subscribers
Pfizer’s RSV shot wins US approval following GSK’s to market
The second vaccine against respiratory syncytial virus has now gained market clearance.
For subscribers
Obesity shot frenzy makes Eli Lilly world’s most valuable drugmaker
After a strong May, Eli Lilly surpasses Johnson & Johnson on market values, becoming the biggest pharma firm in the world.
For subscribers